Grifols closes out 2005 with a 15% increase in turnover

- **Net profit reached 38.5 million euros, nearly doubling profits from 2004.**
  **Sales outside Spain grew 22%, accounting for 70% of the total sales.**

Grifols ended 2005 with a sales figure which reached 524 million euros, a 15% increase from 2004.

The increase in demand for Grifols products, principally plasma derivatives such as Immunoglobulin Intravenous (IGIV) in international markets explains this significant increase in turnover. In 2005, 70% of sales from the group came from international markets and reached 367 million euros, increasing 22.3% from the previous year. The United States generated 149 million euros, growing 62.4% compared to 2004. Turnover in Spain was 157 million euros, 11.3% higher than 2004.

The **Bioscience Division**, which includes all products and activities related to plasma for therapeutic use (plasma derivatives), generated 69.5% of the turnover for the group in 2005. Sales reached 364.2 million euros, an increase of 18.9% compared to 2004.

The **Hospital Division** specializes in pharmaceutical products and medical devices destined for use in hospital pharmacies. Sales from this line increased 6.9% compared to the previous year to reach 58.3 million euros. Currently, this division accounts for 11% of total sales.

The **Diagnostic Division** focuses on clinical in Vitro diagnostics and generated a sales income of 69.6 million euros. Compared to 2004, this is an increase of 11.5% and currently accounts for 13.3% of the business.